Exscientia pays $20M for full control of CDK7 drug, plans breast cancer combo trial

Exscientia pays $20M for full control of CDK7 drug, plans breast cancer combo trial

Submitted by admin on July 18, 2024 - 11:10am
Source: 
Fierce Biotech
News Tags: 
Exscientia
GT Apeiron
M&A
breast cancer
GTAEXS617
Headline: 
Exscientia pays $20M for full control of CDK7 drug, plans breast cancer combo trial
snippet: 

Exscientia has taken full ownership of its oral CDK7 inhibitor candidate, buying out partner GT Apeiron for $20 million. The AI-enabled biotech plans to advance the molecule into a breast cancer combination trial.

Do Not Allow Advertisers to Use My Personal information